T cell co-receptor clustering for cancer treatment
This technology is a SLAMF6 bispecific antibody to enhance T-cell activation through compartmentalization that can be used for tumor treatments.
Unmet Need: Safe and targeted T-cell activation for cancer immunotherapy
Current cancer immunotherapies involve inhibition of checkpoint receptors between T cells and tumor cells. These treatments present limitations such as patient unresponsiveness and immune-related adverse events. There is a need to develop highly targeted therapies that reduce the risk of non-specific T-cell activation. Clustering receptors in specific locations on the cell surface is key to enhance T-cell activity.
The Technology: Bispecific co-receptor antibodies for targeted T-cell activation
This technology describes bispecific monoclonal antibodies that target SLAMF6 co-receptors. SLAMF6 is required for T-cell activation, and its location on the cell surface can affect T-cell functions. By promoting or inhibiting SLAMF6 with different TCR complex such as CD3 or CD45, T-cell activation is enhanced. Additionally, antibodies targeting co-receptor functions reduce the risk of activating resting T-cells, minimizing off-target effects.
This technology has been validated with human cells.
Applications:
- Immunotherapy for cancer treatment
- Research model for studying co-receptor clustering and T cell activation
- Targeted T-cell therapeutic intervention
- Immunomodulation therapy
Advantages:
- Precise compartmentalization
- Avoids non-specific T-cell activation
- Reduced risk of adverse inflammatory immune related effects
- Compatibility with existing therapies
Lead Inventor:
Patent Information:
Patent Pending
Related Publications:
Tech Ventures Reference:
IR CU22398
Licensing Contact: Cynthia Lang